This module uses fundamental data of Shuttle Pharmaceuticals to approximate its Piotroski F score. Shuttle Pharmaceuticals F Score is determined by combining nine binary scores representing 3 distinct fundamental categories of Shuttle Pharmaceuticals. These three categories are profitability, efficiency, and funding. Some research analysts and sophisticated value traders use Piotroski F Score to find opportunities outside of the conventional market and financial statement analysis.They believe that some of the new information about Shuttle Pharmaceuticals financial position does not get reflected in the current market share price suggesting a possibility of arbitrage. Check out Shuttle Pharmaceuticals Altman Z Score, Shuttle Pharmaceuticals Correlation, Shuttle Pharmaceuticals Valuation, as well as analyze Shuttle Pharmaceuticals Alpha and Beta and Shuttle Pharmaceuticals Hype Analysis.
As of now, Shuttle Pharmaceuticals' Net Debt To EBITDA is increasing as compared to previous years. The Shuttle Pharmaceuticals' current Interest Debt Per Share is estimated to increase to 0.22, while Short and Long Term Debt Total is projected to decrease to under 998.4 K. As of now, Shuttle Pharmaceuticals' Days Payables Outstanding is increasing as compared to previous years. The Shuttle Pharmaceuticals' current Net Debt To EBITDA is estimated to increase to 0.39, while PTB Ratio is projected to decrease to 13.56.
At this time, it appears that Shuttle Pharmaceuticals' Piotroski F Score is Poor. Although some professional money managers and academia have recently criticized Piotroski F-Score model, we still consider it an effective method of predicting the state of the financial strength of any organization that is not predisposed to accounting gimmicks and manipulations. Using this score on the criteria to originate an efficient long-term portfolio can help investors filter out the purely speculative stocks or equities playing fundamental games by manipulating their earnings..
The critical factor to consider when applying the Piotroski F Score to Shuttle Pharmaceuticals is to make sure Shuttle is not a subject of accounting manipulations and runs a healthy internal audit department. So, if Shuttle Pharmaceuticals' auditors report directly to the board (not management), the managers will be reluctant to manipulate simply due to the fear of punishment. On the other hand, the auditors will be free to investigate the ledgers properly because they know that the board has their back. Below are the main accounts that are used in the Piotroski F Score model. By analyzing the historical trends of the mains drivers, investors can determine if Shuttle Pharmaceuticals' financial numbers are properly reported.
One of the toughest challenges investors face today is learning how to quickly synthesize historical financial statements and information provided by the company, SEC reporting, and various external parties in order to project the various growth rates. Understanding the correlation between Shuttle Pharmaceuticals' different financial indicators related to revenue, expenses, operating profit, and net earnings helps investors identify and prioritize their investing strategies towards Shuttle Pharmaceuticals in a much-optimized way.
F-Score is one of many stock grading techniques developed by Joseph Piotroski, a professor of accounting at the Stanford University Graduate School of Business. It was published in 2002 under the paper titled Value Investing: The Use of Historical Financial Statement Information to Separate Winners from Losers. Piotroski F Score is based on binary analysis strategy in which stocks are given one point for passing 9 very simple fundamental tests, and zero point otherwise. According to Mr. Piotroski's analysis, his F-Score binary model can help to predict the performance of low price-to-book stocks.
Book Value Per Share
0.27
As of now, Shuttle Pharmaceuticals' Book Value Per Share is increasing as compared to previous years.
About Shuttle Pharmaceuticals Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Shuttle Pharmaceuticals's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Shuttle Pharmaceuticals using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Shuttle Pharmaceuticals based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
When determining whether Shuttle Pharmaceuticals offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Shuttle Pharmaceuticals' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Shuttle Pharmaceuticals Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Shuttle Pharmaceuticals Stock:
For more detail on how to invest in Shuttle Stock please use our How to Invest in Shuttle Pharmaceuticals guide.You can also try the USA ETFs module to find actively traded Exchange Traded Funds (ETF) in USA.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Shuttle Pharmaceuticals. If investors know Shuttle will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Shuttle Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share
(4.25)
Return On Assets
(0.62)
Return On Equity
(1.86)
The market value of Shuttle Pharmaceuticals is measured differently than its book value, which is the value of Shuttle that is recorded on the company's balance sheet. Investors also form their own opinion of Shuttle Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is Shuttle Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Shuttle Pharmaceuticals' market value can be influenced by many factors that don't directly affect Shuttle Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Shuttle Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if Shuttle Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Shuttle Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.